4 hours Ago By Defense World Staff
Ironwood Pharmaceuticals ( NASDAQ:IRWD – Free Report ) had its price objective trimmed by JMP Securities from $23.00 to $14.00 in a research note released on Thursday morning, Benzinga reports.
The brokerage currently has a market outperform rating on the biotechnology company’s stock. Several other equities analysts have also weighed in on IRWD. Craig Hallum dropped their price objective on shares of Ironwood Pharmaceuticals from $10.
00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. StockNews.
com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.
67. Check Out Our Latest Analysis on Ironwood Pharmaceuticals Ironwood Pharmaceuticals Price Performance Ironwood Pharmaceuticals ( NASDAQ:IRWD – Get Free Report ) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.
02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07).
Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.
The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million.
During the same period last year, the business earned $0.12 EPS. The business’s quarterly revenue was down 19.
4% compared to the same quarter last year. Analysts anticipate that Ironwood Pharmaceuticals will post 0.08 EPS for the current year.
Insider Buying and Selling at Ironwood Pharmaceuticals In other news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.
08. Following the completion of the sale, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76.
This represents a 3.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink .
Company insiders own 12.90% of the company’s stock. Institutional Inflows and Outflows Hedge funds and other institutional investors have recently added to or reduced their stakes in the company.
CIBC Asset Management Inc purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth $53,000. Principal Financial Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 4.
0% during the 4th quarter. Principal Financial Group Inc. now owns 765,356 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 29,629 shares during the period.
Rhumbline Advisers boosted its holdings in shares of Ironwood Pharmaceuticals by 3.0% in the 4th quarter. Rhumbline Advisers now owns 348,006 shares of the biotechnology company’s stock worth $1,542,000 after buying an additional 10,041 shares during the last quarter.
Journey Strategic Wealth LLC purchased a new position in shares of Ironwood Pharmaceuticals in the 4th quarter worth about $45,000. Finally, China Universal Asset Management Co. Ltd.
grew its position in Ironwood Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co.
Ltd. now owns 33,932 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 3,209 shares during the period. Ironwood Pharmaceuticals Company Profile ( Get Free Report ) Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. Recommended Stories Five stocks we like better than Ironwood Pharmaceuticals 10 Best Airline Stocks to Buy ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains Profitably Trade Stocks at 52-Week Highs Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead With Risk Tolerance, One Size Does Not Fit All Beyond Self-Driving Cars: Factory Automation Takes Center Stage Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
